Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PepCan
- Development stage
- Phase 2
- Lead developer
- University of Arkansas for Medical Sciences
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
PepCan is a therapeutic vaccine candidate developed for the treatment of Human Papillomavirus (HPV) 16-positive cervical intraepithelial neoplasia (CIN) 2/3. The vaccine formulation consists of four synthetic long peptides (SLPs) covering the entire sequence of the HPV 16 E6 oncoprotein. It is administered intradermally with *Candida albicans* skin test antigen, which serves as a novel adjuvant to enhance the cellular immune response. By stimulating HPV 16 E6-specific T-cell activity, PepCan aims to induce the regression of high-grade cervical lesions and clear persistent HPV infection. The vaccine was developed by researchers at the University of Arkansas for Medical Sciences (UAMS).
- Brand names
- PepCan
- Other names
- HPV 16 E6 peptide vaccineHPV16 E6 peptide vaccineHPV-16 E6 peptide vaccineHPV 16 E6 SLP vaccineHPV16 E6 SLP vaccineHPV-16 E6 SLP vaccine
02
Targets
Human papillomavirus type 16 E6-specific T-cell receptorHPV16 E6 oncoprotein
Beyond the preview
Go deeper on PepCan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PepCan.